Use of androgen deprivation therapy in prostate cancer: Indications and prevalence

Asian Journal of Andrology

Volumn 14, Issue 2, 2012, Pages 177-186

  Connolly, Roisin M ^a   Carducci, Michael A ^a   Antonarakis, Emmanuel S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

androgen deprivation therapy; androgen synthesis; anti androgen; prostate cancer

Indexed keywords

ABARELIX; ABIRATERONE; ABIRATERONE ACETATE; AMINOGLUTETHIMIDE; ANDROGEN; ANDROGEN RECEPTOR ANTAGONIST; ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; DEGARELIX; DOCETAXEL; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; HISTRELIN; HYDROCORTISONE; KETOCONAZOLE; LEUPRORELIN; MITOXANTRONE; MVD 3100; NILUTAMIDE; PREDNISONE; TRIPTORELIN; UNCLASSIFIED DRUG;

ADRENAL INSUFFICIENCY; ADVANCED CANCER; ALLERGIC REACTION; AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; ANTIANDROGEN THERAPY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER SURVIVAL; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; DRUG MECHANISM; EXTERNAL BEAM RADIOTHERAPY; EYE DISEASE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEART DISEASE; HOT FLUSH; HUMAN; HYPERTENSION; HYPOKALEMIA; INJECTION SITE PAIN; LIBIDO DISORDER; LYMPH NODE METASTASIS; MASTALGIA; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA AND VOMITING; NEUROMUSCULAR DISEASE; ORCHIECTOMY; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; REVIEW; SIDE EFFECT; SKIN DISEASE; SWEAT; TREATMENT INDICATION; WEIGHT GAIN;

ANDROGEN ANTAGONISTS; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HUMANS; MALE; PREVALENCE; PROSTATIC NEOPLASMS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SURVIVAL RATE;

EID: 84858045491     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2011.103     Document Type: Review

References (77)

1. http://www.seer.cancer.gov/statfacts/html/prost.html. Accessed online June 7th 2011.
2. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997; 79: 235-46.
3. Krsmanovic LZ, Hu L, Leung PK, Feng H, Catt KJ. The hypothalamic GnRH pulse generator: multiple regulatory mechanisms. Trends Endocrinol Metab 2009; 20: 402-8.
4. Dufau ML, Catt KJ. Gonadotropin receptors and regulation of steroidogenesis in the testis and ovary. Vitam Horm 1978; 36: 461-592.
5. Means AR, Fakunding JL, Huckins C, Tindall DJ, Vitale R. Follicle-stimulating hormone, the Sertoli cell, and spermatogenesis. Recent Prog Horm Res 1976; 32: 477-527.
6. Federman DD. The biology of human sex differences.NEngl J Med 2006; 354: 1507-14.
7. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002; 168: 9-12.
8. Byar DP. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973; 32: 1126-30.
9. Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004; 22: 2927-41. (Pubitemid 41079913)
10. Limonta P, Montagnani Marelli M, Moretti RM. LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drugs 2001; 10: 709-20. (Pubitemid 32288188)
11. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000; 132: 566-77. (Pubitemid 30171897)
12. http://www.nccn.org/professionals/physician-gls/pdf/prostate.pdf. Accessed online April 22nd 2011.
13. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010; 8: 162-200.
14. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74. (Pubitemid 28445094)
15. Antonarakis ES, Blackford AL, Garrett-Mayer E, Eisenberger MA. Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review. J Clin Oncol 2007; 25: 4998-5008. (Pubitemid 350220434)
16. Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 2002; 90: 561-6.
17. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 1995; 154: 424-8.
18. Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR et al. 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 2000; 38: 706-13.
19. Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001; 166: 500-6; discussion 506-7. (Pubitemid 32652231)
20. Selli C, Montironi R, Bono A, Pagano F, Zattoni F et al. Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer. J Clin Pathol 2002; 55: 508-13. (Pubitemid 34779302)
21. Pagliaro LC, Zurita AJ, Araujo JC, Ward JF, Davis JW et al. Presurgical docetaxel (Doc) and androgen deprivation therapy (ADT) in lymph node-positive prostate cancer (PCa). J Clin Oncol 2011; 29 (Suppl): abstract 4619.
22. Messing EM, Manola J, Yao J, Kiernan M, Crawford D et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472-9. (Pubitemid 43779173)
23. Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol 2011; 29: 2040-5.
24. Bolla M, van Poppel H, Tombal B. 10-year results of adjuvant radiotherapy after radical prostatectomy in pT3N0 prostate cancer (EORTC 22991) (abstract). Int J Radiat Biol Phys 2010; 78: s29.
25. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009; 181: 956-62.
26. Whittington R, Broderick GA, Arger P, Malkowicz SB, Epperson RD et al. The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1999; 44: 1107-10. (Pubitemid 29342912)
27. Zelefsky MJ, Leibel SA, Burman CM, Kutcher GJ, Harrison A et al. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 1994; 29: 755-61. (Pubitemid 24241315)
28. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroceA et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 821-7. (Pubitemid 39079668)
29. Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl JMed 2011; 365: 107-18.
30. Lawton CA, DeSilvio M, RoachM3rd, Uhl V, Kirsch R et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007; 69: 646-55. (Pubitemid 47418390)
31. Crook J, Ludgate C, Malone S, Lim J, Perry G et al. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004; 60: 15-23. (Pubitemid 39165464)
32. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300. (Pubitemid 27318990)
33. Bolla M, Collette L, Blank L, Warde P, Dubois JB et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-6.
34. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61: 1285-90. (Pubitemid 40470408)
35. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-52. (Pubitemid 32727802)
36. Denham JW, Steigler A, Lamb DS, Joseph D, Turner S et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011; 12: 451-9.
37. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26: 2497-504.
38. Bolla M, de Reijke TM, van Tienhoven G, van den Bergh AC, Oddens J et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360: 2516-27.
39. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008; 300: 173-81. (Pubitemid 351969301)
40. Schroder FH, Kurth KH, Fossa SD, Hoekstra W, Karthaus PP et al. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846-a phase III study. J Urol 2004; 172: 923-7. (Pubitemid 39096424)
41. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009; 373: 301-8.
42. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001; 165: 1146-51. (Pubitemid 32210224)
43. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-7. (Pubitemid 29211767)
44. Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 2012; 109: 32-9.
45. Antonarakis ES, Chen Y, Elsamanoudi SI, Brassell SA, da Rocha MV et al. Long-term overall survival and metastasis-free survival for men with prostate-specific antigenrecurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. BJU Int 2011; 108: 378-85.
46. Shipley WU, Hunt D, Lukka HR, Major P, Heney NM et al. Initial report of RTOG 9601, a phase III trial in prostate cancer: effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3,N0 disease and elevated PSA levels. J Clin Oncol 2011; 29 (Suppl 7): abstract 1.
47. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25: 1596-605.
48. Treatment and survival of patients with cancer of the prostate. The Veterans Administration Co-operative Urological Research Group. Surg Gynecol Obstet 1967; 124: 1011-7.
49. Thorpe SC, Azmatullah S, Fellows GJ, Gingell JC, O'Boyle PJ. A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol 1996; 29: 47-54. (Pubitemid 26009294)
50. Gravis G, Fizazi K, Joly F, Oudard S, Priou F et al. PSA response and early PSA progression evaluated in patients randomized in a phase III trial comparing androgen-deprivation therapy (ADT) plus docetaxel versus ADT alone in hormonenaive metastatic prostate cancer (GETUG-AFU 15/0403). J Clin Oncol 2011; 29 (Suppl 7): abstract 10.
51. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 1566-72. (Pubitemid 23228264)
52. Ferring Pharmaceuticals Inc. Firmagon prescribing information, December 2008. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/ 022201lbl.pdf. Accessed online December 23rd 2011.
53. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008; 102: 1531-8.
54. Shore ND, Moul JW, Crawford E, van der Meulen E, Olesen T et al. Prostate-specific antigen (PSA) progression-free survival (PFS): a comparison of degarelix versus leuprolide in patients with prostate cancer. J Clin Oncol 2011; 29 (Suppl 7): abstract 12.
55. Steinberg M. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer. Clin Ther 2009; 31: 2312-31.
56. Pont A, Williams PL, Azhar S, Reitz RE, Bochra C et al. Ketoconazole blocks testosterone synthesis. Arch Intern Med 1982; 142: 2137-40. (Pubitemid 12007067)
57. Eichenberger T, Trachtenberg J, Toor P, Keating A. Ketoconazole: a possible direct cytotoxic effect on prostate carcinoma cells. J Urol 1989; 141: 190-1. (Pubitemid 19028867)
58. Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004; 22: 1025-33. (Pubitemid 41095034)
59. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
60. Scher HI, Heller G, Molina A, Kheoh TS, Attard G et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J Clin Oncol 2011; 29 (Suppl): abstract LBA4517.
61. Antonarakis ES, Eisenberger MA. Expanding treatment options for metastatic prostate cancer. N Engl J Med 2011; 364: 2055-8.
62. Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 2009; 115: 3437-45.
63. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 2000; 355: 1491-8.
64. Schmitt B, Wilt TJ, Schellhammer PF, DeMasi V, Sartor O et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 2001; 57: 727-32.
65. Walczak JR, Carducci MA. Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin Proc 2007; 82: 243-9. (Pubitemid 46198485)
66. Studer UE, Hauri D, Hanselmann S, Chollet D, Leisinger HJ et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol 2004; 22: 4109-18. (Pubitemid 41185180)
67. Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006; 24: 1868-76. (Pubitemid 46638985)
68. McLeod DG, Iversen P, See WA, Morris T, Armstrong J et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006; 97: 247-54.
69. Quon H, Loblaw DA. Androgen deprivation therapy for prostate cancer-review of indications in 2010. Curr Oncol 2010; 17 (Suppl 2): S38-44.
70. Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009; 55: 1269-77.
71. Crook JM, O'Callaghan CJ, Ding K, Duncan G, Dearnaley DP et al. A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013). J Clin Oncol 2011; 29 (Suppl): abstract 4514.
72. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005; 103: 1615-24. (Pubitemid 40490022)
73. Gilbert SM, Kuo YF, Shahinian VB. Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States. Urol Oncol 2011; 29: 647-53.
74. Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med 2010; 363: 1822-32.
75. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer. J Clin Oncol 2007; 25: 5359-65. (Pubitemid 350232210)
76. Klotz L, O'Callaghan CJ, Ding K, Dearnaley DP, Higano CS et al. A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013. J Clin Oncol 2011; 29 (Suppl 7): abstract 3.
77. Scher HI, Logothetis C, Molina A, Goodman OB, Sternberg CN et al. Improved survival outcomes in clinically relevant patient subgroups from COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in patients with metastatic castrationresistant prostate cancer (mCRPC) progressing after docetaxel-based chemotherapy. J Clin Oncol 2011; 29 (Suppl 7): abstract 4.